Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva
Fibrodysplasia ossificans progressiva (FOP) is an ultrarare congenital disease that progresses through intermittent episodes of bone formation at ectopic sites. FOP patients carry heterozygous gene point mutations in activin A receptor type I <i>ACVR1</i>, encoding the bone morphogenetic...
Main Authors: | Francesc Ventura, Eleanor Williams, Makoto Ikeya, Alex N. Bullock, Peter ten Dijke, Marie-José Goumans, Gonzalo Sanchez-Duffhues |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/2/213 |
Similar Items
-
Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis
by: Daniele De Brasi, et al.
Published: (2021-07-01) -
Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects
by: Pignolo Robert J, et al.
Published: (2011-12-01) -
Fibrodysplasia ossificans progressiva: “A skeleton within a skeleton”
by: Kasturi Hazarika, et al.
Published: (2021-01-01) -
Neofunction of ACVR1 in fibrodysplasia ossificans progressiva
by: Hino, Kyosuke
Published: (2016) -
ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a
by: Jun Cheng, et al.
Published: (2012-02-01)